Theralase Press Release Updates Bladder Cancer Clinical Study
Theralase has provided an update on the ongoing clinical study of Ruvidar (aka TLD1433) to treat bladder cancer. Key results indicate Total Response (CR + IR) 72.1% (49/68) of patients achieved complete destruction of their bladder cancer at any point in time and 27.9% (19/68) had a duration of this…